TESAROVA, B., S. DOSTALOVA, V. SMIDOVA, Zita GOLIÁŠOVÁ, Z. SKUBALOVA, H. MICHALKOVA, H. DAVID, P. MICHALEK, Hana POLANSKÁ, M. VACUOVICOVA, J. HACEK, T. ECKSCHLAGER, M. STIBOROVA, A. S. PIRES, A. R. M. NEVES, A. M. ABRANTES, T. RODRIGUES, P. MATAFOME, M. F. BOTELHO, P. TEIXEIRA, F. MENDES and Z. HEGER. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. APPLIED MATERIALS TODAY. AMSTERDAM: ELSEVIER SCIENCE BV, 2020, vol. 18, MAR 2020, p. 1-11. ISSN 2352-9407. Available from: https://dx.doi.org/10.1016/j.apmt.2019.100501.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine
Authors TESAROVA, B. (203 Czech Republic), S. DOSTALOVA (203 Czech Republic), V. SMIDOVA (203 Czech Republic), Zita GOLIÁŠOVÁ (203 Czech Republic), Z. SKUBALOVA (203 Czech Republic), H. MICHALKOVA (203 Czech Republic), H. DAVID (203 Czech Republic), P. MICHALEK (203 Czech Republic), Hana POLANSKÁ (203 Czech Republic, belonging to the institution), M. VACUOVICOVA (203 Czech Republic), J. HACEK (203 Czech Republic), T. ECKSCHLAGER (203 Czech Republic), M. STIBOROVA (203 Czech Republic), A. S. PIRES (620 Portugal), A. R. M. NEVES (620 Portugal), A. M. ABRANTES (620 Portugal), T. RODRIGUES (620 Portugal), P. MATAFOME (620 Portugal), M. F. BOTELHO (620 Portugal), P. TEIXEIRA (620 Portugal), F. MENDES (620 Portugal) and Z. HEGER (203 Czech Republic, guarantor).
Edition APPLIED MATERIALS TODAY, AMSTERDAM, ELSEVIER SCIENCE BV, 2020, 2352-9407.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30404 Biomaterials
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 10.041
RIV identification code RIV/00216224:14110/20:00115972
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.apmt.2019.100501
UT WoS 000530652300014
Keywords in English Biocompatibility; Breast carcinoma; Cancer therapy; Ferritin; PASylation; PEGylation
Tags 14110515, 14110518, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 7/10/2021 17:13.
Abstract
Surface functionalisations substantially influence the performance of drug delivery vehicles by improving their biocompatibility, selectivity and circulation in bloodstream. Herein, we present the study of in vitro and in vivo behaviour of a highly potent cytostatic alkaloid ellipticine (Elli) encapsulated in internal cavity of ferritin (FRT)-based nanocarrier (hereinafter referred to as FRTElli). In addition, FRTElli surface was functionalised with three different molecular coatings: two types of protective PAS peptides (10- or 20-residues lengths) with sequences comprising amino acids proline (P), alanine (A) and serine (S) (to form PAS-10-FRTElli or PAS-20-FRTElli, respectively), or polyethylene glycol (PEG-FRTElli). All three surface modifications of FRT disposed sufficient encapsulation efficiency of Elli with no premature cumulative release of cargo. Noteworthy, all tested surface modifications displayed beneficial effects on the in vitro biocompatibility. PAS-10-FRTElli exhibited markedly reduced uptake by macrophages compared to PAS-20-FRTElli, PEG-FRTElli or unmodified FRTElli. The exceptional properties of PAS-10-FRTElli were validated by an array of in vitro analyses including formation of protein corona, uptake efficiency or screenings of selectivity of cytotoxicity. In murine preclinical model bearing triple -negative breast cancer (MDA-MB-231) xenograft, compared to free Elli or FRTElli, PAS-10-FRTElli displayed enhanced accumulation of Elli within tumour tissue, while hampering the uptake of Elli into off-target tissues. Noteworthy, PAS-10-FRTElli led to decreased in vivo complement (C3) activation and protein corona formation. Taken together, presented in vivo results indicate that PAS-10-FRTElli represents a promising stealth platform for translation into clinical settings. (C) 2019 Elsevier Ltd. All rights reserved.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
PrintDisplayed: 13/7/2024 17:14